Skip to content

Cannabis and schizophrenia spectrum disorders: a review of clinical studies.

Chaturaka Rodrigo, Senaka Rajapakse

Indian journal of psychological medicine July 1, 2009 DOI: 10.4103/0253-7176.63575 via PubMed

Summary

AI-generated from the abstract

Cannabis use has increased by 10% worldwide over the last decade, prompting a review of its possible link to schizophrenia spectrum disorders (SSD). The authors searched MEDLINE and other sources for English-language articles from 1999-2009. They discuss biochemical evidence on cannabinoids and the endocannabinoid system, and clinical studies on cannabis, psychosis proneness, and SSD. Three hypotheses are examined: that cannabis causes SSD, that schizophrenic patients are attracted to cannabis, and that cannabis and psychosis proneness have synergistic effects in a vulnerable minority. The evidence does not firmly support causation or self-medication; the most plausible explanation is a synergistic effect in some individuals.

Study at a glance

Characteristics Review Cross-sectional Peer reviewed
Topics Cannabis
Keywords Schizophrenia spectrum disorders
Key finding The exact relationship between cannabis and schizophrenia spectrum disorders is unclear; the most plausible explanation is that cannabis use and psychosis proneness may have synergistic effects in a vulnerable minority.

Abstract

Cannabis is the most widely used illegitimate substance in the world, and the number of users has increased by 10% over the last decade worldwide. Therefore, it is important to review the evidence on psychoactive properties of cannabis and its possible association with schizophrenia spectrum disorders (SSD). We searched MEDLINE with the key words cannabis and schizophrenia. The search was limited to articles published in English over the last 10 years (1999-2009). Bibliographies of cited literature were also searched. Data sources included reviews published in core clinical journals, cohort studies, interventional studies, case-control studies, cross-sectional analyses and epidemiological data. Results are discussed under 2 topics. Firstly, evidence related to biochemical functioning of cannabinoids and their relationship to endocannabinoid system is discussed briefly. Secondly, the evidence from clinical studies on cannabis, psychosis proneness and SSD are discussed in detail. The discussion is structured to fit in the evidence from results section to 3 plausible hypotheses on cannabis use and SSD. The evidence for and against each hypothesis is discussed. Despite new evidence, the exact relationship between cannabis and SSD is unclear. There is no firm evidence that cannabis causes SSD. The evidence for the argument that schizophrenic patients are attracted to cannabis is also not strong. The most plausible explanation is that cannabis use and psychosis proneness may have synergistic effects in a vulnerable minority.

Explore topics

Comments

No comments yet.

Log in to comment